QTERN
PeakNDAORALTABLET
Approved
Feb 2017
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 5h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QTERN is an oral small-molecule tablet approved by FDA in February 2017 under an NDA by AstraZeneca. The specific indication and mechanism of action are not disclosed in available data, limiting clinical context for career evaluation. As a peak-lifecycle product, it represents an established commercial asset rather than a development-stage opportunity.
$2MPart D
Peak3.9 years to LOELow Medicare Part D spending ($2M in 2023) suggests niche indication or market maturity; commercial teams are likely focused on market defense rather than growth acceleration.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
QTERN (SAXAGLIPTIN/DAPAGLIFLOZIN FDC) Regulatory Post-Marketing Surveillance
Started Dec 2021
679 enrolled
Type 2 Diabetes Mellitus
Why This Matters for Your Career
Worked on QTERN at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.